Replies to post #424619 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The Partex thing is great idea, but at this stage not much more. It will take years before we might see any benefit from that partnership, assuming Anavex ever get so far as to have an approved drug.

Since the first approval could be in Rett, as a rare disease with an already closely followed patient population and collaborations collecting data and doing science, it is hard see what value Partex would bring. Don't think that community needs a Partex/Anavex App anytime soon.

The partnership purpose is captured in this paragraph from the Anavex PR Announcement.

Under the partnership, Anavex and Partex intend to co-develop a disease-focused Patient App ecosystem. The first feature will be to inform patients and caregivers on preventive and curative options available in clinics and on the market. Further, Partex will implement AI-based ‘Healthcare Sales Marketing’ in preparation for Anavex’s late stage drug pipeline.

Of course it is labelled a "Strategic Partnership" and as we know strategic at Anavex takes a long time to develop with several detours along the way. We are far away from any Patient App ecosystem existing around Anavex with a patient population and large enough dataset for any AI to do anything with.